|
KR101483215B1
(ko)
*
|
2010-01-29 |
2015-01-16 |
한미약품 주식회사 |
단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
|
|
CA2802641C
(en)
|
2010-07-13 |
2019-03-12 |
Nidhi Arora |
Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators
|
|
EP3239154A1
(en)
|
2011-01-10 |
2017-11-01 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
EP2688872A4
(en)
*
|
2011-03-22 |
2014-08-27 |
Merck Sharp & Dohme |
AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES
|
|
US9309250B2
(en)
|
2011-06-22 |
2016-04-12 |
Vertex Pharmaceuticals Incorporated |
Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
|
|
JP5797345B2
(ja)
*
|
2011-12-30 |
2015-10-21 |
ハンミ ファーム． シーオー．， エルティーディー． |
プロテインキナーゼに対する阻害活性を有するチエノ［３，２−ｄ］ピリミジン誘導体
|
|
RU2637925C2
(ru)
*
|
2012-01-10 |
2017-12-08 |
Ф. Хоффманн-Ля Рош Аг |
Соединения тиенопиримидина
|
|
WO2013106535A1
(en)
|
2012-01-10 |
2013-07-18 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
WO2014003483A1
(en)
*
|
2012-06-29 |
2014-01-03 |
Hanmi Pharm. Co., Ltd. |
Fused pyrimidine derivatives having inhibitory activity on fms kinases
|
|
CA2878621C
(en)
|
2012-07-10 |
2020-09-15 |
Ares Trading S.A. |
Pyrimidine pyrazolyl derivatives
|
|
EP2872144A4
(en)
|
2012-07-11 |
2015-12-02 |
Nimbus Iris Inc |
IRAQ INHIBITOR AND USES THEREOF
|
|
US20140018361A1
(en)
*
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
JP2015528801A
(ja)
|
2012-07-11 |
2015-10-01 |
ニンバス アイリス， インコーポレイテッド |
Ｉｒａｋ阻害剤およびその使用
|
|
PL3808749T3
(pl)
|
2012-12-07 |
2023-07-10 |
Vertex Pharmaceuticals Incorporated |
Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych
|
|
HK1216859A1
(zh)
|
2013-01-10 |
2016-12-09 |
Nimbus Iris, Inc. |
Irak抑制劑和其用途
|
|
EP2943485B1
(en)
|
2013-01-14 |
2017-09-20 |
Incyte Holdings Corporation |
Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
|
|
HUE050215T2
(hu)
|
2013-01-15 |
2020-11-30 |
Incyte Holdings Corp |
Pim kináz inhibitorokként hasznos tiazolkarboxamid és piridinkarboxamid vegyületek
|
|
US8778365B1
(en)
|
2013-01-31 |
2014-07-15 |
Merz Pharmaceuticals, Llc |
Topical compositions and methods for making and using same
|
|
JP2016512239A
(ja)
|
2013-03-15 |
2016-04-25 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ａｔｒキナーゼの阻害剤として有用な化合物
|
|
EP2970288A1
(en)
*
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
JP2016512815A
(ja)
|
2013-03-15 |
2016-05-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
EP3019171B1
(en)
*
|
2013-07-11 |
2018-09-05 |
Merck Sharp & Dohme Corp. |
Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
|
|
TW201605866A
(zh)
*
|
2013-08-23 |
2016-02-16 |
英塞特公司 |
可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物
|
|
CA2925211A1
(en)
|
2013-09-27 |
2015-04-02 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
PL3077397T3
(pl)
|
2013-12-06 |
2020-04-30 |
Vertex Pharmaceuticals Inc. |
Związek 2-amino-6-fluoro-n-[5-fluoro-pirydyn-3-ylo]pyrazolo [1,5-a]pirymidino-3-karboksamidu przydatny jako inhibitor kinazy atr, jego wytwarzanie, różne postacie stałe i ich radioznakowane pochodne
|
|
EP3079682A4
(en)
|
2013-12-13 |
2017-08-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
|
AU2014361798B2
(en)
|
2013-12-13 |
2020-06-11 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
|
TWI667233B
(zh)
|
2013-12-19 |
2019-08-01 |
德商拜耳製藥公司 |
新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
|
|
HK1231480A1
(zh)
|
2014-01-10 |
2017-12-22 |
Aurigene Discovery Technologies Limited |
作为irak4抑制剂的吲唑化合物
|
|
US9732095B2
(en)
|
2014-01-13 |
2017-08-15 |
Aurigene Discovery Technologies Limited |
Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US9346815B2
(en)
*
|
2014-05-23 |
2016-05-24 |
Genentech, Inc. |
5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof
|
|
SG10201902206QA
(en)
|
2014-06-05 |
2019-04-29 |
Vertex Pharma |
Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
|
|
PT3157566T
(pt)
|
2014-06-17 |
2019-07-11 |
Vertex Pharma |
Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr
|
|
WO2016010897A1
(en)
|
2014-07-14 |
2016-01-21 |
Incyte Corporation |
Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
|
|
US9580418B2
(en)
|
2014-07-14 |
2017-02-28 |
Incyte Corporation |
Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
|
|
EP3715346B1
(en)
|
2014-10-22 |
2024-01-03 |
Dana-Farber Cancer Institute, Inc. |
Thiazolyl-containing compounds for treating proliferative diseases
|
|
US20170333435A1
(en)
|
2014-11-06 |
2017-11-23 |
Lysosomal Therapeutics Inc. |
Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
|
|
WO2016073891A1
(en)
|
2014-11-06 |
2016-05-12 |
Lysosomal Therapeutics Inc. |
Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
|
|
KR102662215B1
(ko)
|
2014-11-06 |
2024-05-02 |
비알 - 알&디 인베스트먼츠, 에스.에이. |
치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도
|
|
PT3221306T
(pt)
*
|
2014-11-20 |
2020-02-19 |
Merck Patent Gmbh |
Compostos de heteroarilo como inibidores de irak e utilização dos mesmos
|
|
US10329294B2
(en)
|
2015-03-12 |
2019-06-25 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of IRAK4 activity
|
|
US10329295B2
(en)
|
2015-03-12 |
2019-06-25 |
Merck Sharp & Dohme Corp. |
Pyrrolotriazine inhibitors of IRAK4 activity
|
|
EP3268003B1
(en)
*
|
2015-03-12 |
2020-07-29 |
Merck Sharp & Dohme Corp. |
Thienopyrazine inhibitors of irak4 activity
|
|
EP3268367B8
(en)
|
2015-03-12 |
2022-11-16 |
Merck Sharp & Dohme LLC |
Carboxamide inhibitors of irak4 activity
|
|
EP3268004B1
(en)
*
|
2015-03-12 |
2019-12-18 |
Merck Sharp & Dohme Corp. |
Pyrrolopyridazine inhibitors of irak4 activity
|
|
US9540347B2
(en)
|
2015-05-29 |
2017-01-10 |
Incyte Corporation |
Pyridineamine compounds useful as Pim kinase inhibitors
|
|
WO2017004134A1
(en)
*
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
EP3322698A4
(en)
*
|
2015-07-15 |
2019-01-09 |
Aurigene Discovery Technologies Limited |
INDAZOL AND AZAINDAZONE COMPOUNDS AS IRAQ-4 INHIBITORS
|
|
TWI734699B
(zh)
|
2015-09-09 |
2021-08-01 |
美商英塞特公司 |
Ｐｉｍ激酶抑制劑之鹽
|
|
MX382996B
(es)
*
|
2015-09-17 |
2025-03-13 |
Hope City |
Inhibidores de pcna
|
|
CN105237414B
(zh)
*
|
2015-09-30 |
2017-03-22 |
浙江永宁药业股份有限公司 |
ivacaftor中间体及其制备方法和用途
|
|
RU2768621C1
(ru)
|
2015-09-30 |
2022-03-24 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr
|
|
WO2017059251A1
(en)
|
2015-10-02 |
2017-04-06 |
Incyte Corporation |
Heterocyclic compounds useful as pim kinase inhibitors
|
|
EP3394066A2
(en)
*
|
2015-12-22 |
2018-10-31 |
H. Hoffnabb-La Roche Ag |
PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
|
|
WO2017176961A1
(en)
|
2016-04-06 |
2017-10-12 |
Lysosomal Therapeutics Inc. |
Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
|
|
US11192892B2
(en)
|
2016-04-06 |
2021-12-07 |
Bial—R&D Investments, S.A. |
Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders
|
|
JP7034935B2
(ja)
|
2016-04-06 |
2022-03-14 |
リソソーマル・セラピューティクス・インコーポレイテッド |
ピロロ［１，２－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
|
|
WO2017192841A1
(en)
*
|
2016-05-04 |
2017-11-09 |
Lysosomal Therapeutics Inc. |
Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
|
|
WO2017192930A1
(en)
*
|
2016-05-05 |
2017-11-09 |
Lysosomal Therapeutics Inc. |
SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
|
|
US11345698B2
(en)
|
2016-05-05 |
2022-05-31 |
Bial—R&D Investments, S.A. |
Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
|
|
CN106222183B
(zh)
*
|
2016-07-25 |
2019-11-08 |
南通大学 |
靶向人irak1基因的小干扰rna及其应用
|
|
WO2018083085A1
(en)
|
2016-11-02 |
2018-05-11 |
F. Hoffmann-La Roche Ag |
PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
|
|
MX394556B
(es)
|
2017-02-01 |
2025-03-24 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Derivados de n1-(4-(5-(ciclopropilmetil)-1-metil-1h-pirazol-4-il) piridin-2-il) ciclohexano-1,4-diamina y compuestos relacionados como inhibidores de ck1 y/o irak1 para tratar cáncer.
|
|
JOP20180011A1
(ar)
|
2017-02-16 |
2019-01-30 |
Gilead Sciences Inc |
مشتقات بيرولو [1، 2-b]بيريدازين
|
|
CN110691589A
(zh)
|
2017-03-31 |
2020-01-14 |
奥列基因发现技术有限公司 |
用于治疗血液病的化合物和组合物
|
|
CN106946890A
(zh)
*
|
2017-04-26 |
2017-07-14 |
中国药科大学 |
吡啶类irak4抑制剂、其制备方法及应用
|
|
BR112019024322A2
(pt)
|
2017-05-22 |
2020-06-16 |
F. Hoffmann-La Roche Ag |
Compostos e composições terapêuticos e métodos de uso dos mesmos
|
|
EP3642199B1
(en)
*
|
2017-06-21 |
2022-04-27 |
F. Hoffmann-La Roche AG |
Benzofurans as irak4 modulators
|
|
CN111094292A
(zh)
*
|
2017-06-21 |
2020-05-01 |
豪夫迈·罗氏有限公司 |
作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
|
|
JP2020524663A
(ja)
*
|
2017-06-21 |
2020-08-20 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｉｒａｋ４調節因子としてのイソインドリノン誘導体
|
|
WO2019001460A1
(zh)
*
|
2017-06-27 |
2019-01-03 |
南京明德新药研发股份有限公司 |
作为 irak4 抑制剂的稠环化合物
|
|
JP7114394B2
(ja)
*
|
2017-08-18 |
2022-08-08 |
住友化学株式会社 |
化合物、レジスト組成物及びレジストパターンの製造方法
|
|
EP3684365A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND USES OF SUCH
|
|
EP3684366A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES OF THE LATEST
|
|
FI3704108T3
(fi)
|
2017-10-31 |
2024-05-23 |
Curis Inc |
Irak4-estäjä yhdistelmässä bcl-2-estäjän kanssa käytettäväksi syövän hoitoon
|
|
WO2019099926A1
(en)
|
2017-11-17 |
2019-05-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
EP3717492B1
(en)
|
2017-11-30 |
2023-05-24 |
Hanmi Pharm. Co., Ltd. |
Thieno[3,2-d]pyrimidine compound having inhibitory activity for protein kinase
|
|
WO2019111218A1
(en)
|
2017-12-08 |
2019-06-13 |
Cadila Healthcare Limited |
Novel heterocyclic compounds as irak4 inhibitors
|
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
|
CN112236429B
(zh)
*
|
2018-04-05 |
2024-10-11 |
默克专利有限公司 |
用作ii型irak抑制剂的杂芳基化合物及其用途
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
EP3817822A4
(en)
|
2018-07-06 |
2022-07-27 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
|
TWI898556B
(zh)
|
2018-07-13 |
2025-09-21 |
美商基利科學股份有限公司 |
吡咯并[1,2-b]嗒衍生物
|
|
CN110862375B
(zh)
*
|
2018-08-27 |
2022-10-25 |
深圳铂立健医药有限公司 |
吡唑化合物及其药物组合物和应用
|
|
SG11202104229WA
(en)
|
2018-10-30 |
2021-05-28 |
Kronos Bio Inc |
Compounds, compositions, and methods for modulating cdk9 activity
|
|
SG11202105424PA
(en)
|
2018-11-30 |
2021-06-29 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2020263980A1
(en)
*
|
2019-06-27 |
2020-12-30 |
Biogen Ma Inc. |
Imidazo[1,2-a]pyridinyl derivatives and their use in the treatment of disease
|
|
AU2020360000B2
(en)
|
2019-10-02 |
2023-04-20 |
Kainos Medicine, Inc. |
N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient
|
|
MX2022007576A
(es)
|
2019-12-17 |
2022-09-23 |
Kymera Therapeutics Inc |
Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
IL297050A
(en)
|
2020-04-04 |
2022-12-01 |
Pfizer |
Methods of treating the 2019 corona virus disease
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
EP4223750B1
(en)
*
|
2020-09-30 |
2025-06-25 |
Asahi Kasei Pharma Corporation |
Nitrogen-containing bicyclic compounds which contain pyrimidine as interleukin 1 receptor-associated kinase 4 (irak-4) inhibitors to be used in the treatment of inflammatory or autoimmune diseases
|
|
US11866405B2
(en)
|
2020-12-10 |
2024-01-09 |
Astrazeneca Ab |
Substituted indazoles as IRAK4 inhibitors
|
|
AU2021413371A1
(en)
|
2020-12-30 |
2023-07-13 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
AU2022220043A1
(en)
|
2021-02-15 |
2023-08-31 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
IL307465A
(en)
|
2021-04-08 |
2023-12-01 |
Curis Inc |
Combined therapies for cancer treatment
|
|
US12097261B2
(en)
|
2021-05-07 |
2024-09-24 |
Kymera Therapeutics, Inc. |
CDK2 degraders and uses thereof
|
|
KR102869914B1
(ko)
*
|
2021-10-28 |
2025-10-13 |
재단법인 대구경북첨단의료산업진흥재단 |
신규한 티에노[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
|
|
CN118302168A
(zh)
|
2021-10-29 |
2024-07-05 |
凯麦拉医疗公司 |
Irak4降解剂和其制备
|
|
EP4472967A2
(en)
|
2022-01-31 |
2024-12-11 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|